The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development

Journal of Pathology

Volumn 213, Issue 4, 2007, Pages 360-368

  Liu, G ^a   Terzian, T ^a   Xiong, S ^a   Van Pelt, C S ^a   Audiffred, A ^a   Box, N F ^b   Lozano, G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell cycle arrest; Cerebellar proliferation; Haematopoiesis; Spermatogenesis

Indexed keywords

CASPASE 3; DOXORUBICIN; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBELLUM; CONTROLLED STUDY; DNA DAMAGE; HEMATOPOIESIS; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SPERMATOGENESIS; STEM CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ALLELES; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBELLUM; GROWTH; HEMATOPOIESIS; MALE; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; SPERMATOGENESIS; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36749082463     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2238     Document Type: Article

References (36)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
3. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001;114:4139-4140.
4. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-2908.
5. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
6. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27.
7. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
8. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
9. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8.
10. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-206.
11. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378:206-208.
12. Chavez-Reyes A, Parant JM, Ameise LL, de Oca Luna RM, Korsmeyer SJ, Lozano G. Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 2003;63:8664-8669.
13. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-734.
14. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713- 723.
15. Momand J, Wu HH, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
16. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Over-expression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 1998;95:15608-15612.
17. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725.
18. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003;23:462-472.
19. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, EI-Naggar AK, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004;36:63-68.
20. Yaylaoglu MB, Titmus A, Visel A, Alvarez-Bolado G, Thaller C, Eichele G. Comprehensive expression atlas of fibroblast growth factors and their receptors generated by a novel robotic in situ hybridization platform. Dev Dyn 2005;234:371-386.
21. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, et al. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 2004;24:8884-8894.
22. Wu WS, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, et al. Slug antagonizes p53-mediated apoptosis of haematopoietic progenitors by repressing puma. Cell 2005;123:641-653.
23. Delia D, Mizutani S, Panigone S, Tagliabue E, Fontaneila E, Asada M, et al. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes. Br J Cancer 2000;82:1938-1945.
24. Nghiem P, Park PK, Kim Ys YS, Desai BN, Schreiber SL. ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 2002;277:4428-4434.
25. Lowe SW. Activation of p53 by oncogenes. Endocr Relat Cancer 1999;6:45-48.
26. Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006;103:19842-19847.
27. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
28. Damelin M, Sun YE, Sodja VB, Bestor TH. Decatenation checkpoint deficiency in stem and progenitor cells. Cancer Cell 2005;8:479- 484.
29. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-626.
30. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004;57:561-576.
31. Schmidt CA, Przybylski GK. What can we learn from leukemia as for the process of lineage commitment in haematopoiesis? Int Rev Immunol 2001;20:107-115.
32. Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet 2003;72:975-983.
33. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002;62:7316-7327.
34. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
35. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005;7:547-559.
36. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-1328.